A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
Clinical trial NCT03398967 · UNKNOWN
Trial details
- NCT number
- NCT03398967
- Sponsor
- Chinese PLA General Hospital
- Status
- UNKNOWN
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-02
- Primary completion
- 2022-05-20
- Enrollment
- 80
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.